BROSSARD, Quebec, Aug. 20, 2024 (GLOBE NEWSWIRE) — Diagnos Inc. (DIAGNOS or the Company) (TSX Enterprise: ADK) (OTCQB: DGNOF) a frontrunner in early detection of important well being points via the usage of its FLAIRE platform primarily based on Synthetic Intelligence (AI), declares right now that its high quality administration system absolutely complies with ISO 13485 commonplace and relevant regulatory necessities for medical gadgets.
As a part of the necessities for the commercialization of our flagship product CARA, DIAGNOS should bear thorough statutory high quality compliance audits underneath the Medical System Single Audit Program (MDSAP). MDSAP is a complete method to high quality administration techniques auditing amongst international locations devoted to reinforce the security of medical gadgets.
I wish to take this chance to thank our workers for his or her laborious work on this vital course of. Our purchasers count on our healthcare options to carry out in compliance with the best high quality requirements and DIAGNOS is ready to meet their expectations. With out this certification we aren’t allowed to promote our options worldwide. This new certification additionally covers all new AI primarily based regulatory necessities which were permitted by a number of governments together with: Canada, USA and European international locations, stated Mr. Yves-Stephane Couture, Chief Working Officer of DIAGNOS.
This enormous achievement from our group comes at a time the place Synthetic Intelligence is rising and we wish to be the chief in our subject. DIAGNOS has reached an inflection level in its gross sales development going from a one check firm for diabetics to an organization offering a collection of checks thereby accelerating profitability and affected person satisfaction. A report from Priority Analysis stated that the worldwide synthetic intelligence (AI) within the healthcare Market dimension, which was USD 19.27 billion in 2023 is estimated at 26.69 billion in 2024 and is anticipated to succeed in round USD 613.81 billion by 2034, increasing at a CAGR of 36.83% from 2024 to 2034, stated Mr. André Larente, President of DIAGNOS.
DIAGNOS is at present within the strategy of acquiring regulatory licences in Canada (Well being Canada) and within the USA (US-FDA) for 4 extra modules to help well being care professionals in figuring out typically irregular via Optical Coherence Tomography retinal photos and within the grading of Fundus photos to detect indicators of Retinopathy for basic public grownup, Age-Associated Macular Degeneration, Diabetic Retinopathy and Hypertensive Retinopathy. DIAGNOS can also be engaged on extra ailments via the usage of the retina imaging. Extra details about these modules might be discovered within the April 16, 2024 press launch on the topic.
About DIAGNOS
DIAGNOS is a publicly traded Canadian company devoted to early detection of important well being issues primarily based on its FLAIRE Synthetic Intelligence (AI) platform. FLAIRE permits for fast modifying and creating of functions equivalent to CARA (Laptop Assisted Retina Evaluation). CARA’s picture enhancement algorithms present sharper, clearer and easier-to-analyze retinal photos. CARA is an economical software for real-time screening of enormous volumes of sufferers.
Extra data is obtainable at www.diagnos.ca and www.sedarplus.com.
This press launch accommodates forward-looking data. We can not assure that the forward-looking data talked about will show to be correct, as there could also be a major discrepancy between precise outcomes or future occasions and people talked about on this assertion. DIAGNOS disclaims any intention or obligation to publicly replace or revise any forward-looking data, whether or not on account of new data, future occasions or in any other case. The forward-looking data contained on this press launch is expressly coated by this warning.
Neither the TSX Enterprise Alternate nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Alternate) accepts duty for the adequacy or accuracy of this launch.
For additional data, please contact:Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450-678-8882 ext. 224alarente@diagnos.ca
Supply: DIAGNOS Inc.
